Home›Research›Compare›BPC-157 vs Ipamorelin
Peptide ComparisonBPC-157 vs Ipamorelin
BPC-157
Body Protection Compound 157
Half-life: Under 30 minutes (plasma); no human PK data
638 providers listed
Ipamorelin
NNC 26-0161
Half-life: 2 hours
463 providers listed
BPC-157 and Ipamorelin target different goals — BPC-157 for tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptide, Ipamorelin for selective GH release without cortisol or prolactin co-stimulation. They're compared here for reference, not as direct substitutes.
BPC-157
Half-life
Under 30 minutes (plasma); no human PK data
Ipamorelin
Half-life
2 hours
BPC-157 and Ipamorelin target different goals — BPC-157 for Tissue Repair, Ipamorelin for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
BPC-157
Ipamorelin
BPC-157
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
+10 more
Ipamorelin
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the managem…
GH secretagogues increase bone mineral content in adult female rats
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
+1 more
About BPC-157
BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.
About Ipamorelin
Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
BPC-157
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
global — WADA
BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.
sourceIpamorelin
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceBPC-157
GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.
Ipamorelin
CJC-1295
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
Sermorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
BPC-157
Ipamorelin
Where to source these peptides
BPC-157
638 listed
Browse directory →
Providers offeringIpamorelin
463 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). BPC-157 vs Ipamorelin — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/bpc-157/ipamorelin